The effectiveness of ibutilide has not been determined in patients with arrhythmias of more than 90 days in duration. Patients with atrial fibrillation of, more than 2 to 3 days duration must be adequately anticoagulated, generally for at least 2 weeks. Ibutilide infusion should be stopped as soon as the presenting arrhythmia is terminated or in the event of sustained or nonsustained ventricular tachycardia, or marked prolongation of QT or QTc. If the arrhythmia does not terminate within 10 minutes after the end of the initial infusion , a second 10-minute infusion of equal strength may be administered 10 minutes after completion of the first infusion. Patients should be observed with continuous EGG monitoring for at least 4 hours following infusion or until QTc has returned to baseline.
Longer monitoring is required if any arrhythmic activity is noted.
Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration whenever solution and container permit. Strict adherence to the use of aseptic technique during the preparation of the admixture is recommended in order to maintain sterility. Federal law prohibits dispensing without prescription.